BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stake Reduced by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,027,568 shares of the biotechnology company's stock after selling 53,748 shares during the quarter. Rice Hall James & Associates LLC owned 0.97% of BioCryst Pharmaceuticals worth $15,207,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $33,000. GAMMA Investing LLC increased its holdings in BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,449 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in BioCryst Pharmaceuticals during the 1st quarter worth approximately $79,000. Raymond James Financial Inc. purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $80,000. Finally, Syon Capital LLC purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $99,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX traded down $0.24 during midday trading on Tuesday, reaching $8.72. 2,682,281 shares of the company traded hands, compared to its average volume of 3,036,552. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.02 and a twelve month high of $11.31. The company has a fifty day moving average price of $10.00 and a 200 day moving average price of $8.66. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -33.54, a price-to-earnings-growth ratio of 2.56 and a beta of 1.04.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BCRX shares. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target for the company. Bank of America boosted their price target on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, July 1st. Barclays boosted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Finally, Wedbush boosted their price target on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $16.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.